Wyckliff Omondi

Mr. Wyckliff Omondi

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Acta Tropica
Verified
Journal Article
Closed access
WOWyckliff Omondi
Wyckliff Omondi
EOEunice A. Owino
Eunice A. Owino
DODavid Odongo
David Odongo
JMJoseph M. Mwangangi
Joseph M. Mwangangi
BTBaldwyn Torto
Baldwyn Torto
David P. TchouassiDavid P. Tchouassi
David P. Tchouassi

8 October 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
YSYao Sodahlon
Yao Sodahlon
DRDavid A. Ross
David A. Ross
CMCarol McPhillips-Tangum
Carol McPhillips-Tangum
JLJoni Lawrence
Joni Lawrence
RTRachel Taylor
Rachel Taylor
MMMwelecele Ntuli Malecela
Mwelecele Ntuli Malecela
Neglected tropical diseases (NTDs) affect more than 1 billion people worldwide and disproportionately trap some of the world's most vulnerable and marginalized populations into a cycle of poverty and disease [1]. Although NTDs place a heavy burden on public health, particularly among low-and middle-income countries, progress has been made over the past few decades. Since the London Declaration in 2012, about 31 countries have eliminated at least one NTD [2]. Much of the progress toward the control and elimination of NTDs is due to three factors: (1) Countries have committed to reaching more people with NTD interventions, (2) the pharmaceutical industry has donated billions of treatments for NTDs, and (3) philanthropists have provided generous funding to implement NTD interventions [3].

3 November 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
HSHadley Matendechero Sultani
Hadley Matendechero Sultani
COCollins Okoyo
Collins Okoyo
HKHenry M. Kanyi
Henry M. Kanyi
SNSammy M. Njenga
Sammy M. Njenga
WOWyckliff Omondi
Wyckliff Omondi
KDKebede Deribe
Kebede Deribe
: Podoconiosis is a type of tropical lymphedema that is clinically distinguished from lymphatic filariasis (LF) because it is ascending and commonly bilateral but asymmetric. The disease is a result of a genetically determined inflammatory reaction to long-term exposure to mineral particles in irritant red clay soils derived mainly from volcanic soils. We conducted the first nationwide mapping of the prevalence and risk factors of podoconiosis in Kenya. We performed a population-based cross-sectional survey to determine the national prevalence of podoconiosis and included 6,228 individuals from 48 villages in 24 sub-counties across 15 counties. Participants answered a questionnaire about the history of symptoms compatible with podoconiosis, received a point-of-care antigen test, and underwent a physical examination if they had lymphedema. A confirmed case of podoconiosis was defined as a case in a resident of the study village who had lower limb bilateral and asymmetric lymphedema lasting more than 1 year, negative test results for Wuchereria bancrofti antigen, and other causes of lymphedema ruled out. Of all the individuals surveyed, 89 had lymphedema; of those, 16 of 6228 (0.3%; 95% confidence interval [CI], 0.1–0.5) were confirmed to have podoconiosis. A high prevalence of podoconiosis was found in western (Siaya, 3.1%; Busia, 0.9%) and central (Meru, 1.1%) regions, and a low prevalence was observed in northern (Marsabit, 0.2%), eastern (Makueni, 0.2%), and coastal (Tana River, 0.1%) regions. The identified risk factors were age 56 years or older (adjusted odds ratio [aOR], 5.66; 95% CI, 2.32–13.83; P < 0.001) and rarely wearing shoes (aOR, 18.92; 95% CI, 4.55–78.71; P < 0.001). These results indicated that the podoconiosis prevalence is low and localized in Kenya; therefore, elimination is achievable if appropriate disease prevention, management, and behavioral strategies are promoted.

15 March 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CKCHRISTABEL KHAEMBA
CHRISTABEL KHAEMBA
ABAbbie Barry
Abbie Barry
WOWyckliff Omondi
Wyckliff Omondi
KBKefa Bota
Kefa Bota
SMSultani Matendechero
Sultani Matendechero
EAEleni Aklillu
Eleni Aklillu
Preventive chemotherapy with diethylcarbamazine citrate (DEC) and albendazole (ALB) is the core intervention strategy to eliminate lymphatic filariasis (LF). We conducted a large-scale prospective active safety surveillance study to identify the incidence, type, severity, and risk factors for adverse events (AEs) following mass drug administration (MDA) of single-dose DEC and ALB in 10,010 participants from Kilifi County, Kenya. AEs were actively monitored and graded at 24 h, 48 h, and on day 7 Post-MDA. Out of 10,010 enrolled study participants, 1621 participants reported a total of 3102 AEs during a seven-day follow-up. The cumulative incidence of AEs was 16.2% (95% CI, 15.5–16.9%). The proportion of participants who experienced one, two, or ≥three types of AEs was 9.2%, 4.6%, 2.4%, respectively. AEs were mild (87.3%), moderate (12.4%), and severe (0.3%) and resolved within 72 h. The five most common AEs were dizziness (5.9%), headache (5.6%), loss of appetite (3.3%), fever (2.9%), and drowsiness (2.6%). Older age, taking concurrent medications, ≥three tablets of DEC, and type of meal taken before MDA were significant predictors of AEs. One in six participants experienced systemic mild-to-moderate severity grading and transient AEs. DEC and ALB co-administration for the elimination of LF is generally safe and well-tolerated.

8 August 2023 in Drug Safety
Verified
Journal Article
Open access
PDF file
CKCHRISTABEL KHAEMBA
CHRISTABEL KHAEMBA
ABAbbie Barry
Abbie Barry
WOWyckliff Omondi
Wyckliff Omondi
EKElvis Kirui
Elvis Kirui
MOMARGARET ODECK OLUKA
MARGARET ODECK OLUKA
EAEleni Aklillu
Eleni Aklillu
Introduction Dual diethylcarbamazine and albendazole (DA) therapy is the standard mass drug administration (MDA) regimen for lymphatic filariasis in Kenya. Following the recent World Health Organization recommendation, Kenya piloted triple therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) in MDA. Objective We conducted a community-based, observational, cohort event monitoring study to compare the types, frequency, severity, and predictors of adverse events following dual versus triple therapy in 20,421 eligible residents. Methods Residents in Kilifi (n = 10,010) and Mombasa counties (n = 10,411) received DA and IDA through MDA campaigns, respectively. Adverse events were actively monitored through house-to-house visits on days 1, 2, and 7 after MDA. Any clinical events reported before and after MDA were cross-checked and verified to differentiate pre-existing events from MDA-associated adverse events. Results Overall, 5807 and 3102 adverse events were reported by 2839 and 1621 individuals in the IDA and DA groups, respectively. The incidence of experiencing one or more adverse events was significantly higher (p < 0.0001) in the IDA group (27.3%; 95% confidence interval [CI] 26.4–28.2) than in the DA group (16.2%; 95% CI 15.5–16.9). Dizziness (15.9% vs 5.9%) and drowsiness (10.1% vs 2.6%) were the most common adverse events and significantly higher in the IDA group compared with the DA group (p < 0.0001). Most adverse events were mild or moderate with a few severe cases (IDA = 0.05%; 95% CI 0.35–0.78, DA = 0.03%; 95% CI 0.14–0.60). Female sex, obesity, taking three or more diethylcarbamazine or ivermectin tablets, and having pre-existing clinical symptoms were significant predictors of adverse events following IDA treatment. Conclusions Ivermectin, diethylcarbamazine, and albendazole as a combination is as safe and well tolerated as DA to use in MDA campaigns with no serious life-threatening adverse events. Systemic mild-to-moderate adverse events with a few severe cases and transient adverse events are more common with IDA treatment than with DA treatment. Hence, integrating pharmacovigilance into a MDA program is recommended for the timely detection and management of adverse events.

6 June 2022 in Tropical Diseases, Travel Medicine and Vaccines
Verified
Journal Article
Open access
PDF file
LKLydiah W. Kibe
Lydiah W. Kibe
BKBridget W. Kimani
Bridget W. Kimani
COCollins Okoyo
Collins Okoyo
WOWyckliff Omondi
Wyckliff Omondi
HSHadley M. Sultani
Hadley M. Sultani
DNDoris W. Njomo
Doris W. Njomo
Introduction: The Kenya Breaking Transmission Strategy for Neglected Tropical Diseases (NTD) from 2019 to 2023 intensifies advocacy, coordination, and partnerships. The purpose of this study was to explore views and experiences of stakeholders and health workers on ways of improving the Advocacy, Communication and Social Mobilization (ACSM) activities of Mass Drug Administration (MDA) for Lymphatic Filariasis (LF) programs through participatory approaches in Kilifi County, Kenya. Methods: Two wards were purposely selected in the Kaloleni sub-county, Kilifi County, where there was an average treatment coverage of 56% in 2015, 50.5% in 2016. Qualitative data collection methods were employed, which included participatory meetings with county stakeholders to understand their views, experiences, and suggestions on how ACSM strategies can be improved in MDA for LF. Twelve In-Depth Interviews (IDIs) were conducted (six with opinion leaders and six with Community Health Extension Workers (CHEWs) and two semi-structured interviews (SSIs) were held with county and sub-county coordinators involved in MDA administration. The aim was to better to understand their perceptions of the NTD program about ACSM, challenges to ACSM strategies, and ways to improve the strategies for ACSM in MDA for LF. The Data was organized and classified into codes and themes using QSR NVIVO version 12. Results: The study observed the low participation of stakeholders in the ACSM activities of MDA for LF and identified potential areas for stakeholders’ involvement to strengthen the activities. Challenges hindering effective implementation of ACSM activities include late delivery of Information, Educational and Communication (IEC) and few IEC materials, insufficient funding, inadequate time allocated to reach the assigned households with messages, messaging, and packaging of information for dissemination due to the vastness of the area. The stakeholders recommended innovative strategies and techniques to improve ACSM activities. Discussion and conclusion: The results of this study show key challenges to ACSM implementation of MDA for LF. Implementers need to pay attention to these challenges to enhance the effectiveness of MDA per the Kenya NTD Breaking Transmission Strategy. ACSM efforts in MDA for LF control and elimination should be linked with overarching efforts to mainstream partnerships and coordination in control and elimination.